BioCentury
ARTICLE | Distillery Therapeutics

Cancer

November 1, 2016 7:00 AM UTC

Patient sample and mouse studies suggest inhibiting APOBEC3B could help treat estrogen receptor-positive, tamoxifen-resistant breast cancer. In estrogen receptor-positive breast cancer patients treated with tamoxifen, high primary tumor expression of APOBEC3B correlated with poor metastasis-free survival. In a xenograft mouse model of estrogen receptor-positive, tamoxifen-resistant breast cancer, tamoxifen plus shRNA targeting APOBEC3B decreased tumor growth compared with either agent alone. Next steps could include identifying and testing a small molecule APOBEC3B inhibitor. ...